Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Receivables: 2021-2023

Historic Change in Receivables for Relay Therapeutics (RLAY) over the last 3 years, with Dec 2023 value amounting to -$211,000.

  • Relay Therapeutics' Change in Receivables fell 424.62% to -$211,000 in Q4 2023 from the same period last year, while for Dec 2023 it was -$306,000, marking a year-over-year decrease of 215.46%. This contributed to the annual value of -$306,000 for FY2023, which is 215.46% down from last year.
  • Per Relay Therapeutics' latest filing, its Change in Receivables stood at -$211,000 for Q4 2023, which was down 258.65% from $133,000 recorded in Q3 2023.
  • In the past 5 years, Relay Therapeutics' Change in Receivables registered a high of $525,000 during Q3 2021, and its lowest value of -$75.0 million during Q1 2021.
  • For the 3-year period, Relay Therapeutics' Change in Receivables averaged around -$6.3 million, with its median value being -$33,500 (2022).
  • Within the past 5 years, the most significant YoY rise in Relay Therapeutics' Change in Receivables was 382.98% (2023), while the steepest drop was 1,194.74% (2023).
  • Quarterly analysis of 3 years shows Relay Therapeutics' Change in Receivables stood at -$401,000 in 2021, then soared by 116.21% to $65,000 in 2022, then tumbled by 424.62% to -$211,000 in 2023.
  • Its Change in Receivables stands at -$211,000 for Q4 2023, versus $133,000 for Q3 2023 and -$208,000 for Q2 2023.